Affordable Access

Publisher Website

Mirvetuximab soravtansine-gynx: first antibody/antigen-drug conjugate (ADC) in advanced or recurrent ovarian cancer.

Authors
  • Bogani, Giorgio1
  • Coleman, Robert L2
  • Vergote, Ignace3
  • van Gorp, Toon4
  • Ray-Coquard, Isabelle5, 6
  • Oaknin, Ana7
  • Matulonis, Ursula8
  • O'Malley, David9
  • Raspagliesi, Francesco10
  • Scambia, Giovanni11
  • Monk, Bradley J12
  • 1 Department of Surgery, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy [email protected]. , (Italy)
  • 2 Gynecologic Oncology, Texas Oncology Houston Memorial City, Shenandoah, Texas, USA.
  • 3 Department of Gynecology and Obstetrics, Gynecologic Oncology, Leuven Cancer Institute, Catholic University Leuven, Leuven, Belgium. , (Belgium)
  • 4 Gynaecological Oncology, KU Leuven University Hospitals Leuven, Leuven, Belgium. , (Belgium)
  • 5 Centre Leon Berard, LYON CEDEX 08, Centre, France. , (France)
  • 6 Hesper lab, Université Claude Bernard Lyon 1, Villeurbanne, France. , (France)
  • 7 Vall d'Hebron Institute of Oncology, Barcelona, Spain. , (Spain)
  • 8 Dana Farber Cancer Institute, Boston, Massachusetts, USA.
  • 9 The Ohio State University Comprehensive Cancer Center Arthur G James Cancer Hospital and Richard J Solove Research Institute, Columbus, Ohio, USA.
  • 10 Deparment of Surgery, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy. , (Italy)
  • 11 Dipartimento Scienze della Salute della Donna e del Bambino, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy. , (Italy)
  • 12 Virginia G Piper Cancer Center - Biltmore Cancer Center, Phoenix, Arizona, USA.
Type
Published Article
Journal
International Journal of Gynecological Cancer
Publisher
Ovid Technologies (Wolters Kluwer) - Lippincott Williams & Wilkins
Publication Date
Apr 01, 2024
Volume
34
Issue
4
Pages
469–477
Identifiers
DOI: 10.1136/ijgc-2023-004924
PMID: 38101816
Source
Medline
Keywords
Language
English
License
Unknown

Abstract

Mirvetuximab soravtansine-gynx (MIRV) is a conjugate of a folate receptor alpha (FRα)-directed antibody and the maytansinoid microtubule inhibitor, DM4. Accumulating pre-clinical and clinical data supported the safety and anti-tumor activity of MIRV in tumors expressing FRα. In 2017, a phase I expansion study reported the first experience of MIRV in FRα-positive platinum-resistant ovarian cancer with promising results. However, the phase III FORWARD I study failed to demonstrate a significant benefit of MIRV in FRα-positive tumors. On the basis of the data reported from this latter study, MIRV was then explored in the FRα-high population only and using a different folate receptor assay. The phase II SORAYA trial supported the adoption of MIRV in this setting. Hence, the US Food and Drug Administration granted accelerated approval of MIRV for patients with FRα-positive platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received 1-3 prior systemic treatment regimens. Moreover, the results of the MIRASOL trial showed a significant reduction in the risk of tumor progression or death among patients treated with MIRV versus chemotherapy. VENTANA FOLR1 (FOLR-2.1) was approved as a companion diagnostic test to identify FRα patients. MIRV appears to be a significant asset in managing advanced or recurrent ovarian cancer. Further trials are needed to confirm these promising results, even in the neoadjuvant, adjuvant, and maintenance settings. © IGCS and ESGO 2024. No commercial re-use. See rights and permissions. Published by BMJ.

Report this publication

Statistics

Seen <100 times